326553 (GWP.L) (GWP) Share Price, News & Analysis

Company Overview

GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company's lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD). The Company offers Sativex (nabiximols), which is indicated for the treatment of spasticity due to multiple sclerosis (MS). The Company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. The Commercial segment distributes and sells the Company's commercial products. The Sativex Research and Development segment seeks to maximize the potential of Sativex through the development of new indications. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using its cannabinoid technology platform.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 2.32 million shs
• Average Volume: 956,721 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GWP Stock Analysis - Frequently Asked Questions

How do I buy shares of 326553 (GWP.L)?

Shares of GWP stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What other stocks do shareholders of 326553 (GWP.L) own?

Based on aggregate information from My MarketBeat watchlists, some other companies that 326553 (GWP.L) investors own include GW Pharmaceuticals (GWPH), Canopy Growth (CGC), Aurora Cannabis (ACB), Cronos Group (CRON), Immunomedics (IMMU), Alibaba Group (BABA) and Cara Therapeutics (CARA).

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: LON:GWP
• CUSIP: N/A
• CIK: N/A
• Web: www.gwpharm.com
• Phone: +44-1223-266800
• Fax: N/A
• Employees: 496
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A